These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26898029)

  • 21. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
    Naumann M; Yakovleff A; Durif F;
    J Neurol; 2002 Jan; 249(1):57-63. PubMed ID: 11954869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Applications of botulinum toxin in Neurology].
    Garcia-Ruiz PJ
    Med Clin (Barc); 2013 Jul; 141(1):33-6. PubMed ID: 23434466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
    Defazio G; Abbruzzese G; Girlanda P; Vacca L; Currà A; De Salvia R; Marchese R; Raineri R; Roselli F; Livrea P; Berardelli A
    Arch Neurol; 2002 Mar; 59(3):418-20. PubMed ID: 11890846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
    J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.
    Tan EK; Jankovic J
    Neurology; 1999 Dec; 53(9):2102-7. PubMed ID: 10599789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.
    Hassell TJW; Charles D
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32331272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frozen versus fresh reconstituted botox for laryngeal dystonia.
    Thomas JP; Siupsinskiene N
    Otolaryngol Head Neck Surg; 2006 Aug; 135(2):204-8. PubMed ID: 16890068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients.
    Poungvarin N; Devahastin V; Chaisevikul R; Prayoonwiwat N; Viriyavejakul A
    J Med Assoc Thai; 1997 Jan; 80(1):1-8. PubMed ID: 9078810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxins in the treatment of primary focal dystonias.
    Truong D
    J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Botulin A toxin: a highly effective drug in the treatment of focal dystonia].
    Timerbaeva SL; Ivanova-Smolenskaia IA; Markova ED; Poleshchuk VV; Karapetian MV; Rebrova OIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(5):32-5. PubMed ID: 10849964
    [No Abstract]   [Full Text] [Related]  

  • 33. Fast voluntary neck movements in patients with cervical dystonia: a kinematic study before and after therapy with botulinum toxin type A.
    Gregori B; Agostino R; Bologna M; Dinapoli L; Colosimo C; Accornero N; Berardelli A
    Clin Neurophysiol; 2008 Feb; 119(2):273-80. PubMed ID: 18063411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of botulinum toxin type A on vibration induced facilitation of motor evoked potentials in spasmodic torticollis.
    Urban PP; Rolke R
    J Neurol Neurosurg Psychiatry; 2004 Nov; 75(11):1541-6. PubMed ID: 15489383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and treatment of abductor hallucis focal dystonia with botulinum toxin injection: a case presentation.
    Rosenberg NS; Odderson IR
    PM R; 2013 Aug; 5(8):726-8. PubMed ID: 23953019
    [No Abstract]   [Full Text] [Related]  

  • 37. Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience.
    Barbosa ER; Takada LT; Gonçalves LR; Costa RM; Silveira-Moriyama L; Chien HF
    Arq Neuropsiquiatr; 2010 Aug; 68(4):502-5. PubMed ID: 20730300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of botulinum toxin type A and its clinical applications in migraine headache.
    Silberstein SD
    Expert Opin Pharmacother; 2001 Oct; 2(10):1649-54. PubMed ID: 11825307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated.
    Batisti JP; Kleinfelder AD; Galli NB; Moro A; Munhoz RP; Teive HA
    Arq Neuropsiquiatr; 2017 Feb; 75(2):87-91. PubMed ID: 28226076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.